甘肃11选5

先声药业:皮下注射PD-L1抗体Envafolimab(KN035)临床试验数据将在ASCO大会发布

asco.png

甘肃11选52020NIAN5YUE15RI,XIANSHENGYAOYEXUANBU,QIYUJIANGSUKANGNINGJIERUISHENGWUZHIYAOYOUXIANGONGSI(YIXIAJIANCHENG“JIANGSUKANGNINGJIERUI”)、SILUDI(BEIJING)YIYAOKEJIYOUXIANGONGSI(YIXIAJIANCHENG“SILUDIYIYAO”)DACHENGZHANLVEHEZUODEXINYIDAIPD-L1KANGTIKN035(TONGYONGMING:Envafolimab)“DANYAOZAIZHONGGUOGAOWEIWEIXINGBUWENDINGXING(MSI-H)ZHONGLIU/CUOPEIXIUFUGONGNENGQUEXIAN(dMMR)WANQISHITILIUHELIANHEHUALIAOZHILIAOWANQIWEIHUOWEISHIGUANJIEHEBU(G/GEJ)ZHONGLIUZHONGDELIANGXIANGGUANJIANLINCHUANGSHUJU”,JIANGYOUHEZUOHUOBANSILUDIYIYAO(3D Medicines)ZAI2020NIANMEIGUOLINCHUANGZHONGLIUXUEHUI(ASCO)NIANHUISHANGZHANSHI。XIANGXISHUJUJIANGYU2020NIAN5YUE29RIZAIGONGSIWANGZHANstb789.comTONGBUFABU。


Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency

(ASCO摘要编号:#3021)

YANJIUSHITANSUOEnvafolimabZHILIAOMSI-H/dMMRWANQISHITILIUDEYIXIANGGUANJIANLINCHUANGSHIYAN,CAIYONGDANBEIKAIFANGBIAOQIANSHEJI,YANJIUZHUYAOZHONGDIANWEIDULISHENPINGWEIYUANHUIPINGJIADEJINGQUERENKEGUANHUANJIELV(ORR)。JIEZHICHANGAI(CRC)HEWEIAI(GC)DEMSI-H/dMMRZHUANGTAICAIYONGZHONGXINSHIYANSHIQUEREN,QITAZHONGLIUCAIYONGDANGDISHIYANSHIPINGGUJIEGUO。FABUDESHIYANSHUJUJIEZHIDAO2019NIAN12YUE17RI。ZHONGGUO25GEZHONGXINZHAOMU103MINGMSI-H / dMMRWANQIAIZHENGHUANZHE。ZHUYAOLIAOXIAORENQUN(PEPi)BAOKUO39LIJIWANGZHISHAOJIESHOUGUOHANFUNIAOMIDINGLEI、AOSHALIBOHEYILITIKANGFANGANZHILIAODEWANQICRCHE11LIJIWANGZHISHAOJIESHOUGUOYIXIANBIAOZHUNZHILIAODEWANQIGC,ZHONGWEISUIFANGSHIJIANWEI7.5GEYUE。 ZONGTIRENQUNBAOKUO65LICRC(24LIXIANQIANJIESHOUGUOFUNIAOMIDINGHEAOSHALIBOHUOYILITIKANGZHILIAO),18LIWEIAIHE20LIQITALIUZHONG,ZHONGWEISUIFANGSHIJIANWEI6.7GEYUE。ZHUYAOLIANGDIANBAOKUO:

1.PEPiRENQUNZHONGJINGQUERENDEKEGUANHUANJIELVWEI30%(95%CI:17.9%,44.6%),80%DEHUANJIELVZAISHUJUJIEZHISHIRENGZAICHIXU。

甘肃11选52.XIANQIANJIESHOUFUNIAOMIDINGHEAOSHALIBOHUOYILITIKANGZHILIAODECRCHUANZHEZHONGWEI54.2%(95%CI:32.8%,74.4%)。

3.ZONGTIRENQUNJINGQUERENDEKEGUANHUANJIELVWEI34.0%(95%CI:24.9%,44.0%),85.7%DEHUANJIEZAISHUJUJIEZHISHIRENGZAICHIXU。

甘肃11选54.PEPiHEZONGTIRENQUNDEZHONGWEIWUJINZHANSHENGCUNQIJUNWEI6.6GEYUE。LIANGGERENQUNZHONGWEIZONGTISHENGCUNJUNWEIDADAO。 14MINGHUANZHE(13.6%)FASHENG3–4JIYUZHILIAOXIANGGUANDEBULIANGSHIJIAN(TRAE)。 MEIYOU5JITRAE、FEIYANHUOJIECHANGYANDEBAODAO。9LIHUANZHEFASHENGLEJUBUZHUSHEBUWEIFANYING,JUNWEI1JIHUO2JI。


Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer

(ASCO摘要编号:#16585)

YANJIUTANSUOEnvafolimabLIANHEFOLFOXZUOWEIWANQIWEIAI/WEISHIGUANJIEHEBUZHONGLIUYIXIANZHILIAODEANQUANXINGHEYOUXIAOXING。FABUSHUJULIANGDIANBAOKUO:

1.GONG15MINGHUANZHELIAOXIAOKEPINGGU。80%SHOUSHIZHEDEECOGPINGFENWEI1。DADUOSHURENWEIWEIAI(86.7%)。SHUJUJIEZHISHI,ZUIDUANSUIFANGSHIJIANWEI6GEYUE。

甘肃11选52.ZHILIAOQIJIANBULIANGSHIJIAN(TEAE)FASHENGLVWEI100%(SUOYOUJIBIE)HE73.3%(3-4JI)。 ZUICHANGJIANDE3-4JITEAEBAOKUOZHONGXINGLIXIBAOJIANSHAO46.7%、PINXUE20.0%、XUEXIAOBANWENLUAN20%(3/15)。

甘肃11选53.QUERENDEORRWEI60%(WUXUQUERENDEORR:73.3%)。

4.ZHONGWEIHUANJIESHIJIAN(DOR)WEIDADAO。ZHONGWEIPFSWEI6.8GEYUE。


先声药业创始人、董事长任晋生先生表示:“自3月30日我们宣布与康宁杰瑞、思路迪医药就Envafolimab达成战略合作以来,各项工作稳步、快速推进中。此次在ASCO会议上公布的临床研究数据显示Envafolimab对多个适应症具有良好的安全性和持久的抗肿瘤活性,让我们对这个具有重大临床价值的皮下注射PD-L1抗体充满信心。先声药业的企业使命是‘让患者早日用上更好药物’,我们会共同努力,尽快将这一令人期待的产品推向市场,造福更多患者。”


关于Envafolimab

Envafolimab(KN035)SHIPD-L1DANYUKANGTIFcDERONGHEDANBAI,JIYUCIDUTESHEJI,ZAIANQUANXING、FANGBIANXING、YICONGXINGFANGMIANJUYOUYOUSHI,KEYONGYUBUSHIHEJINGMAISHUYEDEHUANZHE,TONGSHIJUYOUJIAODIDEYILIAOCHENGBEN。MUQIANZAIZHONGGUO、MEIGUOHERIBENZHENDUIDUOGEZHONGLIUSHIYINGZHENGTONGBUKAIZHANLINCHUANGSHIYAN,BUFENSHIYINGZHENGYIJINRUⅢQILINCHUANG。EnvafolimabYIHUODEMEIGUOFDADEWANQIDANDAOAIGUERYAOZIGERENDING,JIHUA2020NIANJINXINGGUONEIYAOPINZHUCESHENBAO。2020NIAN3YUE30RI,XIANSHENGYAOYE、KANGNINGJIERUI、SILUDIYIYAOSANFANGDACHENGZHANLVEHEZUO,KANGNINGJIERUIZUOWEIYUANYANFANGFUZESHENGCHANHEZHILIANG, SILUDIYIYAOYONGYOUEnvafolimabZAIZHONGLIULINGYUDEQUANQIULINCHUANGKAIFA、ZHUCEYIJIJINGWAISHANGYEHUAQUANYI,XIANSHENGYAOYEFUZECHANPINZAIZHONGGUODALUDEDUJIASHANGYETUIGUANG。


关于先声药业

XIANSHENGYAOYESHIZHONGGUOLINGXIANDEYANFAQUDONGXINGZHIYAOGONGSI,JUJIAOZHONGLIU、SHENJING、ZISHENMIANYIDENGZHONGDAJIBINGLINGYU,HUOPIJIANSHE“ZHUANHUAYIXUEYUCHUANGXINYAOWUGUOJIAZHONGDIANSHIYANSHI”,ZHILIYURANGHUANZHEZAORIYONGSHANGGENGHAOYAOWU。PINGJIEYOUYIDESHANGYEHUANENGLI,QIZHUYAOCHANPINZAIZHONGGUOBAOCHILINGXIANDESHICHANGFENE。XIANSHENGYAOYEBINGCHIKAIFANGSHICHUANGXINDEYANFACELVE,YUDUOJIAKUAGUOYAOQICHENGWEIZHANLVEHEZUOHUOBAN,CUJINQUANQIUSHENGMINGKEXUECHENGGUOZAIZHONGGUODEJIAZHISHIXIAN。

GENGDUOXINXIQINGFANGWEN:stb789.com

相关新闻
    上一篇  关于先声药业